Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
Amnon A. Berger, Ariel Winnick, Alexandra Welschmeyer, et al.
Neurology International (2020) Vol. 12, Iss. 3, pp. 109-129
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

A novel electrochemical sensor based on collaborative performance enhancement of hybrid Acid Orange 10 polymer/zirconium nanoparticles for first voltammetric determination of Istradefylline in plasma
Marwa F. B. Ali, Ibrahim A. Darwısh, Noha M. Hosny
Microchemical Journal (2025), pp. 112911-112911
Closed Access | Times Cited: 2
Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders
Chiara Cervetto, Guido Maura, Diego Guidolin, et al.
Neuropharmacology (2023) Vol. 237, pp. 109636-109636
Open Access | Times Cited: 17
Drugs targeting adenosine signaling pathways: A current view
Barbara Kutryb-Zając, Ada Kawecka, Khrystyna Nasadiuk, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115184-115184
Open Access | Times Cited: 17
The altered TBI fecal microbiome is stable and functionally distinct
Richard B. Pyles, Aaron L. Miller, Randall J. Urban, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 7
Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database
Ying Jiang, Rongrong Lu, Qin Zhou, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
The Good, the Bad, and the Deadly: Adenosinergic Mechanisms Underlying Sudden Unexpected Death in Epilepsy
Benton S. Purnell, Madhuvika Murugan, Raja Jani, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 33
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia
Kärt Mätlik, Daniel R. Garton, Ana Montaño-Rodriguez, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 8, pp. 3247-3261
Open Access | Times Cited: 27
Optical Control of Adenosine A2A Receptor Using Istradefylline Photosensitivity
Anaëlle Dumazer, Xavier Gómez‐Santacana, Fanny Malhaire, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 3, pp. 645-655
Open Access | Times Cited: 5
A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases
Stefania Merighi, Pier Andrea Borea, Katia Varani, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 24, pp. 4138-4151
Open Access | Times Cited: 28
Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
L. Cummins, Marshall E. Cates
Mental Health Clinician (2022) Vol. 12, Iss. 1, pp. 32-36
Open Access | Times Cited: 20
In silico Discovery of Dual Ligands Targeting MAO-B and AA2AR from African Natural Products Using Pharmacophore Modelling, Molecular Docking, and Molecular Dynamics Simulations
Yassir Boulaamane, Iman Touati, Imteyaz Qamar, et al.
Chemistry Africa (2024)
Closed Access | Times Cited: 4
Conventional Pharmacotherapy in Parkinson’s Disease
Erik Ch. Wolters
Cambridge University Press eBooks (2025), pp. 264-279
Closed Access
James Parkinson and Other Historical Aspects of Parkinson’s Disease
Helen L. Dainton-Howard, Christopher G. Goetz
Neurologic Clinics (2025)
Closed Access
Arbutin effectively ameliorates the symptoms of Parkinson’s disease: the role of adenosine receptors and cyclic adenosine monophosphate
Zhihai Yuan, Jie Zhao, Manish Kumar, et al.
Neural Regeneration Research (2021) Vol. 16, Iss. 10, pp. 2030-2030
Open Access | Times Cited: 22
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 3, pp. 873-919
Closed Access | Times Cited: 8
Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
Javed Ahmad, Nafis Haider, Mohammad Ahmed Khan, et al.
Biochemical Pharmacology (2021) Vol. 195, pp. 114849-114849
Closed Access | Times Cited: 17
Drug repurposing for neurodegenerative diseases
Halak Shukla, D. James B. St. John, Shuvomoy Banerjee, et al.
Progress in molecular biology and translational science (2024), pp. 249-319
Closed Access | Times Cited: 2
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST
Takayasu Mishima, Shih‐Wei Chiu, Hidemoto Saiki, et al.
Journal of the Neurological Sciences (2023) Vol. 448, pp. 120619-120619
Closed Access | Times Cited: 5
Expression of the Adenosine A2A-A3 Receptor Heteromer in Different Brain Regions and Marked Upregulation in the Microglia of the Transgenic APPSw,Ind Alzheimer’s Disease Model
Alejandro Lillo, Iu Raïch, Jaume Lillo, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 214-214
Open Access | Times Cited: 8
The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline
Xiaoqin Hu, Jinhuan Ni, Nanyong Gao, et al.
Chemico-Biological Interactions (2022) Vol. 366, pp. 110123-110123
Closed Access | Times Cited: 6
The olfactory Olfr-78/51E2 receptor interacts with the adenosine A2A receptor. Effect of menthol and 1,8-cineole on A2A receptor-mediated signaling
Jaume Lillo, Irene García-Pérez, Alejandro Lillo, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Apomorphine for Parkinson’s disease: pharmacologic and clinical considerations
Maxwell J Wagner, Charles P Daniel, Connor J Plaisance, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 275-281
Closed Access | Times Cited: 3
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential
Andrea Spinaci, Michela Buccioni, Chang Cui, et al.
Topics in medicinal chemistry (2023), pp. 101-141
Closed Access | Times Cited: 2
Efficacy and safety of istradefylline for Parkinson’s disease: A systematic review and meta-analysis
Xiaole Wang, Sitong Feng, Bin Chen, et al.
Neuroscience Letters (2022) Vol. 774, pp. 136515-136515
Closed Access | Times Cited: 3
The adenosine A2A receptor is a therapeutic target in neurological, heart and oncogenic diseases
Rafael Franco, Alejandro Lillo, Gemma Navarro, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 9, pp. 791-800
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top